Amarins Public Company 

$0
4
+$0+0% Saturday 00:07

Statistics

Day High
-
Day Low
-
52W High
152.24
52W Low
152.24
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
May 25
$0
May 24
$0
May 23
$0.01
May 22
$0.01
May 21
$0
10Y Growth
-21.9%
5Y Growth
N/A
3Y Growth
-30.82%
1Y Growth
-62.74%

Earnings

28JulExpected
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
-722
176.49
1,074.99
1,973.48
Expected EPS
1225.53
Actual EPS
0.7954

Financials

1.91%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
114.42MRevenue
2.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMRPF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline plc, a major pharmaceutical company, competes in developing cardiovascular drugs, similar to Amarins' focus on heart health treatments.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. develops innovative human therapeutics, including treatments for cardiovascular disease, directly competing with Amarins' product offerings.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is a broad-based pharmaceutical company that also focuses on cardiovascular health, making it a direct competitor in the same therapeutic area as Amarins.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, known for its extensive research and development in cardiovascular diseases, competes with Amarins in the heart health pharmaceutical market.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. offers a range of health solutions, including cardiovascular drugs, which pits it against Amarins in the market for heart-related treatments.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie Inc. engages in the development of drugs across several therapeutic areas, including cardiovascular diseases, competing with Amarins' specialized products.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC has a strong portfolio in cardiovascular and metabolic diseases, directly competing with Amarins in these healthcare segments.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company, which focuses on innovative medicines including those for cardiovascular diseases, competes with Amarins in developing treatments for heart conditions.
Sanofi
SNY
Mkt Cap124.45B
Sanofi focuses on global healthcare needs including cardiovascular diseases, making it a competitor to Amarins in the market for heart health pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson operates in various healthcare sectors, including the development of cardiovascular drugs, competing with Amarins in the pharmaceutical market.

About

Amarin Printing and Publishing Public Company Limited, together with its subsidiaries, engages in the publishing, advertising, and publications distribution businesses in Thailand. It offers a range of printing services, such as artwork creative design, photography, and image retouching, as well as digital and packaging printing service. The company also conceptualizes, compiles, designs, publishes, and delivers offline content, including books, magazines/newsletters, cards/leaflets/brochures/posters, annual reports, anniversary books, pocket books, and gifts; online content, including e-books, video clips, websites, and applications, as well as augmented reality and social network content; and visual content comprising infographics, illustrations, picture, and photography content. In addition, it engages in the organization of events, fairs, and seminars, as well as offsite training programs for private companies and SMEs; purchase, procurement, lease, and leasehold of various assets; and production, distribution, retail, and wholesale of various publication formats that include Thai and translated foreign language books, Praew and Sudsapda magazines for women, electronic creative media comprising video and multimedia teaching materials, and other printed materials. As of December 31, 2020, it operated 139 bookstores under the Nai-In name. The company was formerly known as Amarin Printing Group Company Limited and changed its name to Amarin Printing and Publishing Public Company Limited in 1993. Amarin Printing and Publishing Public Company Limited was founded in 1976 and is headquartered in Bangkok, Thailand.
Show more...
CEO
Mr. Kyung-Bae Suh
Country
TH
ISIN
TH0277010Z04

Listings

0 Comments

Share your thoughts

FAQ

What is Amarins Public Company stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amarins Public Company stocks are traded under the ticker AMRPF.
What were Amarins Public Company earnings last quarter?
AMRPF earnings for the last quarter are 0.8 USD per share, whereas the estimation was 1,225.53 USD resulting in a -99.94% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amarins Public Company revenue for the last year?
Amarins Public Company revenue for the last year amounts to 114.42M USD.
What is Amarins Public Company net income for the last year?
AMRPF net income for the last year is 2.18M USD.
Does Amarins Public Company pay dividends?
Yes, AMRPF dividends are paid annual. The last dividend per share was 0 USD. As of today, Dividend Yield (FWD)% is 0%.
When did Amarins Public Company complete a stock split?
The last stock split for Amarins Public Company was on April 22, 2015 with a ratio of 10:1.
Where is Amarins Public Company headquartered?
Amarins Public Company is headquartered in Seoul, TH.